The aim of this study was analysis of the results of use of interferon-α (IFN-α) in patients with recurrent respiratory papillomatosis (RRP) and correlation of the results with human papillomavirus (HPV) type.
Methods:
A multicenter prospective series (42 patients from 22 hospitals) yielded 20 years of follow-up of patients with RRP and HPV typing who were treated with IFN-α in doses of 3 MU/m2 3 times per week.
Results:
During long-term follow-up (mean ± SD, 172 ± 36.8 months), the rate of event-free survival evaluated by Kaplan-Meier analysis was 42.8%, and the overall survival rate was 82.6%. The HPV typing revealed an association of HPV 11 with a more aggressive disease course (64% of HPV 11 patients versus 24% of HPV 6 patients), a lower incidence of long-term response to IFN-α therapy (14% of HPV 11 patients versus 64% of HPV 6 patients), and a higher incidence of malignant transformation and mortality during follow-up (36% and 24%, respectively, of HPV 11 patients versus 0% of HPV 6 patients).
Conclusions:
The obtained results revealed maximal effectiveness of IFN-α therapy in RRP patients with HPV 6 as compared with HPV 11. The association of HPV 11 with a worse long-term response to IFN-α therapy and a higher incidence of malignant transformation and mortality is clinically important and indicates the necessity of HPV typing in RRP patients after the first biopsy.
BerglerWFGotteK. Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol2000; 257: 263–9.
2.
KornhuberBGereinVKroppHLodemannEAhrensM. Treatment of severe papillomatosis of the respiratory tract with leucocyte interferon [Abstract]. Monatsschr Kinderheilkd1983; 131: 680.
3.
GissmannLWolnikLIkenbergHKoldovskyUSchnürchHGzur HausenH. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A1983; 80: 560–3.
4.
AaltonenLMRihkanenHVaheriA. Human papillomavirus in larynx. Laryngoscope2002; 112: 700–7.
5.
GabbottMCossartYEKanAKonopkaMChanRRoseBR. Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis. J Clin Microbiol1997; 35: 3098–103.
6.
RimellFLShoemakerDLPouAMJordanJAPostJCEhrlichGD. Pediatric respiratory papillomatosis: Prognostic role of viral typing and cofactors. Laryngoscope1997; 107: 915–8.
7.
GereinVZapfBZennerHSchlöndorfGDrafWPfisterH. Humana Papilloma Virus (HPV)–Nachweis im Verlauf der Alpha-Interferon (IFN)–Therapie der juvenilen Larynxpapillomatose und dessen Bedeutung für die Prognose. In: FleischerK, ed. Kurzreferate der 60. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Part 1. Graefelfing, Germany: Demeter Verlag, 1989: 96–7.
SchoutenTJWeimarWBosJHBosCECremersCWSchellekensH. Treatment of juvenile laryngeal papillomatosis with two types of interferon. Laryngoscope1982; 92: 686–8.
11.
LeventhalBGKashimaHKMountsP. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group. N Engl J Med1991; 325: 613–7.
12.
HealyGBGelberRDTrowbridgeALGrundfastKMRubenRJPriceKN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med1988; 319: 401–7.
13.
DeunasLAlcantudVAlvarezF. Use of interferonalpha in laryngeal papillomatosis: Eight years of the Cuban national programme. J Laryngol Otol1997; 111: 134–40.
14.
LodemannEKornhuberBGereinVvon Il'bergC. (2′-5′)olgo(A) synthetase as a monitor of interferon action in juvenile laryngeal papillomatosis. J Interferon Res1984; 4: 283–90.
15.
GereinVLodemannEBellGv IlbergCKornhuberB. Ergebnisse einer Langzeit-Leukozyten-Interferon (alpha-IFN)–Therapie nach einem individuell ermittelten Dosierungsschema bei rezidivierender Larynxpapillomatose. Klin Padiatr1987; 199: 224–9.
16.
KashimaHLeventhalBMountsPPapilloma Study Group. Scoring system to assess severity and course in recurrent respiratory papillomatosis. In: HowleyPMBrokerTR, eds. Papillomaviruses: Molecular and clinical aspects. New York, NY: Alan R Liss, 1985: 125–35.
17.
HesterRPDerkayCSBurkeBLLawsonML. Reliability of a staging assessment system for recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol2003; 67: 505–9.
18.
GissmannLBoshartMDurstMIkenbergHWagnerDzur HausenH. Presence of human papillomavirus in genital tumors. J Invest Dermatol1984; 83(suppl): 26s–28s.
19.
GereinVEifeRHoltmannH. Abnormalities in production of interferon (IFN) caused by long-term-alfa-IFN therapy in patients with laryngeal papilloma [Abstract]. Blut1986; 53: 230.
20.
GlanzHSchulzAKleinsasserOSchulzeWDreyerTArensC. Benign lesions of the larynx: Basic clinical and histopathological data. International Congress Series 1128, Excerpta Medica. In: KleinsasserOGlanzHOlofssonJ, eds. Advances in laryngology in Europe. Amsterdam, the Netherlands: Elsevier Science, 1997: 3–14.
21.
DedoHHYuKC. CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope2001; 111: 1639–44.
22.
TothovaEStecovaNKafkovaAFricovaMSvorcovaE. Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa [in Slovak]. Vnitr Lek2002; 48: 380–3.
23.
WorleHMaassEKohlerBTreunerJ. Interferon alpha-2a therapy in haemangiomas of infancy: Spastic diplegia as a severe complication. Eur J Pediatr1999; 158: 344.
24.
ArmstrongLRDerkayCSReevesWC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg1999; 125: 743–8.
MountsPKashimaH. Association of human papillomavirus subtype and clinical course in respiratory papillomatosis. Laryngoscope1984; 94: 28–33.
27.
RabahRLancasterWDThomasRGregoireL. Human papillomavirus–11–associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus–6–associated disease. Pediatr Dev Pathol2001; 4: 68–72.
28.
CookJRHillDAHumphreyPAPfeiferJDEl-MoftySK. Squamous cell carcinoma arising in recurrent respiratory papillomatosis with pulmonary involvement: Emerging common pattern of clinical features and human papillomavirus serotype association. Mod Pathol2000; 13: 914–8.
29.
RadyPLSchnadigVJWeissRLHughesTKTyringSK. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope1998; 108: 735–40.
30.
Garcia-MillianRSantosAPereaSEGonzalez-CabanasRValenzuelaCAranaM. Molecular analysis of resistance to interferon in patients with laryngeal papillomatosis. Cytokines Cell Mol Ther1999; 5: 79–85.
31.
PranskySMAlbrightJTMagitAE. Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope2003; 113: 1583–7.
32.
SchraffSDerkayCSBurkeBLawsonL. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg2004; 130: 1039–42.
33.
NaimanANRogerGGagnieuMC. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope2004; 114: 1151–6.
34.
ArmbrusterCKreuzerAVorbachHHuberMArmbrusterC. Successful treatment of severe respiratory papillomatosis with intravenous cidofovir and interferon alpha-2b. Eur Respir J2001; 17: 830–1.
35.
JohnsonTBryderKCorbetSFomsgaardA. Routine genotyping of human papillomavirus samples in Denmark. APMIS2003; 111: 398–404.
